The Effects And Mechanisms Of TNF-α/TNFR2 In Regulatory T Cells On Microenvironment And Progression In Gastric Cancer Read more
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations Read more
?A Phase 1/2, Dose Escalation And Expansion Study Of The Safety, Tolerability, And Anti-Tumor Activity Of BND-22 Administered Alone And In Combination With Pembrolizumab Or With Cetuximab In Patients With Advanced Solid Tumors Read more
Molecular profiling in patients with advanced lung or thymic cancer previously treated with immune checkpoint inhibitor therapy. Read more
A Phase 1, Multicenter, Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of TAB006, As Monotherapy And In Combination With Toripalimab, In Patients With Previously Treated, Advanced Malignancies Read more
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) Read more
Phase I Study Dose Finding Study To Evaluate Safety, Reactogenicity And Immunogenicity Of CV09040102 RAS G12D Mrna Vaccine In HLA- Selected Patients With Pancreatic Cancer Or Colorectal Cancer Harboring The RAS G12D Mutation Read more
A Phase 2 Study Of VS-6766 (Dual RAF/MEK Inhibitor) As A Single Agent And In Combination With Defactinib (FAK Inhibitor) In Recurrent KRAS-Mutant (KRAS-MT) Non-Small Cell Lung Cancer (NSCLC) Read more
